Intraoperative Dual-modality Imaging in Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Intraoperative tumor localization and resection can be enhanced using intraoperative
fluorescence imaging and radiodetection. Girentuximab specifically recognizes carbonic
anhydrase IX expressed on > 95% of renal cell carcinoma (RCC). Therefore
Indium-111-DOTA-girentuximab-IRDye800CW is a perfect dual-labeled antibody for dual-modality
image-guided surgery in RCC.
The aim of this study is to assess the feasibility and safety of intraoperative dual-modality
imaging with Indium-111-DOTA-girentuximab-IRDye800CW in renal cell carcinoma patients.